Trial Profile
Clinical Trial of Avatrombopag for Thrombocytopenia in Cancer, A Phase II Single Arm Study
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 30 Mar 2022
Price :
$35
*
At a glance
- Drugs Avatrombopag (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- 04 Dec 2020 Planned End Date changed from 1 May 2022 to 3 Dec 2020.
- 04 Dec 2020 Planned primary completion date changed from 1 May 2022 to 3 Dec 2020.
- 04 Dec 2020 Status changed from recruiting to withdrawn prior to enrolment.